A. D. Asekritov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
A. D. Asekritov has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- D. V. Solovyova
Medical Institute of North-Eastern Federal University named M.K. Ammosov
1 shared publication - E. A. Ignatiev
Medical Institute of North-Eastern Federal University named M.K. Ammosov
1 shared publication - Ivan O. Popov
Medical Institute of North-Eastern Federal University named M.K. Ammosov
1 shared publication - M. G. Neustroeva
Medical Institute of North-Eastern Federal University named M.K. Ammosov
1 shared publication N. V. Ilyin
Republican Hospital № 1 — National Center of Medicine
1 shared publication- Natalya S. Arkhipova
Republican Hospital № 1 — National Center of Medicine
1 shared publication
Latest Publications
- Open Access
- 4 June 2021
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 99 (1) , 68-74-74
Pulmonary arterial hypertension associated with systemic scleroderma
Pulmonary arterial hypertension (PAH) is an orphan disease characterized by an increase in pulmonary vascular resistance (PVR). PAH is a pathology, difficult to diagnose due to the non-specificity of its first strokes. The prognosis of PAH is extremely unfavorable without early diagnosis and treatment, as with systemic scleroderma, 60% of patients die in the first 2 years. In the Republic of Sakha (Yakutia), there are currently 38 patients with PAH, and a tendency towards an increase in their number is noted. The necessity to conduct scientific research on PAH patients living in the Republic of Sakha (Yakutia) is urgent due to the fact. The article represents a 1.5-year clinical observation of a 45-year-old patient with PAH associated with systemic scleroderma, which demonstrates difficulties in the differential diagnosis of PAH, late initiation of PAH-specific pharmacotherapy. The article discusses the efficiency of the original PAH-specific drugs use, and their generics.
- 4 June 2021
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 99 (1) , 68-74-74
Open AccessPulmonary arterial hypertension associated with systemic scleroderma
Pulmonary arterial hypertension (PAH) is an orphan disease characterized by an increase in pulmonary vascular resistance (PVR). PAH is a pathology, difficult to diagnose due to the non-specificity of its first strokes. The prognosis of PAH is extremely unfavorable without early diagnosis and treatment, as with systemic scleroderma, 60% of patients die in the first 2 years. In the Republic of Sakha (Yakutia), there are currently 38 patients with PAH, and a tendency towards an increase in their number is noted. The necessity to conduct scientific research on PAH patients living in the Republic of Sakha (Yakutia) is urgent due to the fact. The article represents a 1.5-year clinical observation of a 45-year-old patient with PAH associated with systemic scleroderma, which demonstrates difficulties in the differential diagnosis of PAH, late initiation of PAH-specific pharmacotherapy. The article discusses the efficiency of the original PAH-specific drugs use, and their generics.